<DOC>
	<DOC>NCT02598583</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety, tolerability and efficacy of multiple IV doses of ALXN1210 administered to patients with PNH</brief_summary>
	<brief_title>An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>1. Male or female â‰¥ 18 years of age 2. PNH diagnosis confirmed by documented highsensitivity flow cytometry 3. Documented meningococcal vaccination not more than 3 years prior to dosing 4. Female patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210. 5. Willing and able to give written informed consent and comply with the study visit schedule 1. Treatment with a complement inhibitor at any time 2. Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1 3. Participation in an interventional clinical study within 30 days before initiation of dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on Day 1, or within 5 half lives of the product, whichever is greater 4. History of allergy to excipients of ALXN1210 or known allergy to Chinese hamster ovary (CHO) cell proteins 5. Inability to comply with study requirements 6. History of any clinically significant cardiac, hepatic, immunologic, pulmonary, or rheumatoid disease that, in the Investigator's judgment, would preclude participation 7. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the patient unsuitable for enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>PNH</keyword>
	<keyword>complement inhibitor</keyword>
</DOC>